Kenvue Inc. (KVUE)

What is Kenvue, and how is it different from Johnson & Johnson?

Kenvue was carved out of Johnson & Johnson in August 2023 as a newly independent, publicly traded company focused on consumer healthcare products sold over the counter. For decades, these products — Tylenol, Motrin, Sudafed, Listerine, and others — lived inside the sprawling Johnson & Johnson conglomerate alongside prescription drugs and medical devices. Spinning them off created a company sized to compete with other consumer-healthcare firms like Haleon (which houses Advil and GSK’s consumer brands) and Procter & Gamble’s health division, while allowing Johnson & Johnson to focus on higher-margin prescription pharmaceuticals and device businesses. Kenvue inherited a portfolio of familiar household brands and the infrastructure to manufacture, distribute, and market them globally, but without the umbrella of a major pharmaceutical company.

What makes Kenvue’s business model tick?

The economics of consumer healthcare are simpler than those of prescription drugs. Patients find a brand on the shelf, decide to buy it based on trust and price, and take it home without a doctor’s prescription. That means no need to navigate insurance or regulatory approval for minor variations — the friction is low, and switching costs are low too. Kenvue makes money by selling high volumes of products with modest margins per unit, the opposite of the prescription business where a single drug can cost thousands and carry huge margins. The company’s power comes from brand recognition and shelf space; Tylenol and Motrin are so familiar that consumers often ask for them by name, which gives Kenvue pricing power even in a crowded pain-relief aisle.

The bulk of Kenvue’s revenue comes from pain relievers (acetaminophen and ibuprofen products), cold and cough medicines, allergy treatments, and gastrointestinal remedies sold under brands like Tylenol, Motrin, Sudafed, and Imodium. The company also owns personal care products including Listerine oral care and various other health and hygiene items. These categories are mature — consumer behaviour around cold relief or pain treatment does not change rapidly — so growth comes from pricing, geographic expansion in emerging markets, and gradual shifts in consumer preferences (toward gummies, new flavours, or premium formulations). The company also earns licensing fees when other firms use the brand name under contract.

What is the strategic advantage, and what threatens it?

Kenvue’s advantage is brand equity accumulated over decades. Tylenol is so embedded in consumer consciousness that it has become almost synonymous with acetaminophen for a generation of buyers. That equity commands shelf space, supports premium pricing relative to generic equivalents, and creates switching costs — habit and familiarity are real. The company also owns a global distribution network built into pharmacies, supermarkets, and online retailers, and manufacturing capability across multiple continents.

The threats are equally straightforward. Generics are cheap, effective, and increasingly available both in physical stores and online. A consumer who once felt they had to buy Tylenol can now easily discover that a store-brand acetaminophen costs a quarter of the price and works identically. That race to the bottom happens slowly but steadily. Additionally, the rise of telehealth and direct-to-consumer pharmaceuticals may erode the over-the-counter market if more conditions shift to prescription-only or if consumers can obtain medications directly from online doctors without visiting a pharmacy. Finally, Kenvue operates in a heavily regulated industry; changes to labelling rules, approval processes, or permitted ingredient combinations can be costly and slow.

How does Kenvue compete in a world full of generics?

The company’s survival depends on brand strength and operational efficiency. It spends on advertising and retail partnerships to maintain the brand’s visibility and shelf prominence, especially in emerging markets where Tylenol is less entrenched than in North America. It introduces line extensions — flavoured formulations, rapid-acting versions, combination products — to justify modest price premiums over generic versions. It pursues geographic growth, particularly in Asia and Latin America, where rising incomes and modernising retail mean more consumers can afford branded over-the-counter products. And it works relentlessly on cost reduction, since lower manufacturing and distribution costs let it maintain margins even when retail prices face pressure.

What are the financial realities?

Kenvue inherited strong brands but also inherited an expected split from Johnson & Johnson that came with debt, one-time expenses, and the need to stand alone operationally. The company must now handle its own regulatory affairs, supply chain management, and technology infrastructure — things that Johnson & Johnson once provided. That means higher costs relative to when it was a division, at least in the near term. However, the business model itself is cash-generative; over-the-counter products sold in high volume and with established supply chains produce reasonable free cash flow, and the company is committed to returning capital to shareholders through dividends and buybacks despite carrying some debt from the separation.

Where should a reader focus when evaluating Kenvue?

Start with the company’s annual 10-K filing (SEC CIK 0001944048), which itemises revenue by geography and product category and details the separation costs and debt burden. Watch quarterly earnings for trends in volume versus pricing — does the company grow by selling more products or by raising prices on existing products? Growing volume in emerging markets is healthier than volume stagnation offset by aggressive price increases. Look at the gross margin trajectory; if it is shrinking, Kenvue may be losing share to generics or competitors. Monitor the company’s free cash flow; as the debt from separation is repaid, available cash for dividends should rise. Finally, keep an eye on regulatory developments around over-the-counter drug labelling and approvals, which can change the cost structure of the business unpredictably. The stock trades on the NYSE under KVUE and, like any publicly traded security, its share price reflects market expectations of future earnings — nothing here should be construed as investment advice.